Current and future therapies for the treatment of histamine-induced angioedema.

Abstract:

INTRODUCTION:Angioedema, a sudden, self-limited swelling of localized areas of any part of the body that may or may not be associated with urticaria, is thought to be the result of a mast-cell mediated process versus a bradykinin etiology. Understanding the mechanism is key in determining the proper treatment. Areas Covered: Clinical presentation of varying angioedema types may be similar; however, the appropriate treatment algorithm is dependent upon clinicians' knowledge of the underlying pathophysiology and classification of angioedema. Literature review of recent guidelines, available medications, and alternative therapies was completed to provide an overview of options. CONCLUSION:There are no formal guidelines for treatment of acute or chronic histamine-mediated angioedema, and therefore, algorithms for the treatment of acute and chronic urticaria should be followed until such information becomes available. Differentiating histamine-mediated versus bradykinin mediated angioedema is essential, as treatments and treatment responses are quite different. Further research is needed to better understand idiopathic angioedema that is unresponsive to H1/H2 antagonists, LTMAs, or medications designed to treat bradykinin-mediated angioedema.

authors

James C,Bernstein JA

doi

10.1080/14656566.2017.1282461

subject

Has Abstract

pub_date

2017-02-01 00:00:00

pages

253-262

issue

3

eissn

1465-6566

issn

1744-7666

journal_volume

18

pub_type

杂志文章,评审
  • Oseltamivir in the management of influenza.

    abstract::Seasonal influenza causes significant morbidity and mortality in adults and children. However, a worldwide influenza pandemic could cause considerably more deaths (20-40 million) and would majorly disrupt everyday life in most countries. Oseltamivir has proven to be safe and effective for the prevention or treatment o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.14.2493

    authors: Oxford J

    更新日期:2005-11-01 00:00:00

  • Dehydroepiandrosterone for the treatment of systemic lupus erythematosus.

    abstract::The adrenal steroidal hormone dehydroepiandrosterone (DHEA) has been studied as a potential pharmacological agent in the treatment of the autoimmune disease systemic lupus erythematosus (SLE). Both the endocrine effects (the ability to be converted peripherally to androgenic and oestrogenic sex steroids) and the immun...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.1.23

    authors: van Vollenhoven RF

    更新日期:2002-01-01 00:00:00

  • Photodynamic therapy using 5-aminolaevulinic acid for the treatment of dysplasia in Barrett's oesophagus.

    abstract:BACKGROUND:5-Aminolaevulinic acid (ALA) is the naturally occurring metabolic precursor of an endogenously formed photosensitiser, protoporphyrin IX. It is used topically to treat benign and malignant skin disorders by a process called photodynamic therapy (PDT). Recently, data are emerging on its systemic use in the tr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.5.851

    authors: Dunn J,Lovat L

    更新日期:2008-04-01 00:00:00

  • Immunosuppressive therapy of childhood idiopathic nephrotic syndrome.

    abstract::Childhood nephrotic syndrome (NS) is a distressing chronic renal disorder with potentially life threatening complications. Over 80% of cases in children are due to minimal change disease and the majority will respond to corticosteroid therapy. Steroid-sensitive NS is considered a relatively benign condition, since pro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.5.513

    authors: Abeyagunawardena A,Brogan PA,Trompeter RS,Dillon MJ

    更新日期:2002-05-01 00:00:00

  • Pharmacotherapy of hypercholesterolaemia: statins in clinical practice.

    abstract::The objective of this article is to evaluate the roles of the lipid-lowering class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in reducing cardiovascular events and to review their mechanism of action based on in vitro and in vivo studies. The clinical outcome of 15 major clinical...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.4.683

    authors: Moghadasian MH,Mancini GB,Frohlich JJ

    更新日期:2000-05-01 00:00:00

  • Pharmacological management of pulmonary embolism.

    abstract:INTRODUCTION:Pulmonary embolism (PE) is a common and potentially severe manifestation of venous thromboembolism. Its management has relied on anticoagulation by vitamin K antagonists (VKA) for the past fifty years. Recently, new alternative drugs have been developed and dramatically modified both the treatment of acute...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1268122

    authors: Gouin B,Robert-Ebadi H,Righini M,Blondon M

    更新日期:2017-01-01 00:00:00

  • An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.

    abstract:INTRODUCTION:Phosphodiesterase type 5 inhibitors (PDE5-i) are used for the oral treatment of erectile dysfunction (ED). Since the launch of sildenafil more than 15 years ago, new molecules have become available. At present, in addition to tadalafil and vardenafil, there are three other drugs, udenafil, avanafil and mir...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.799665

    authors: Bruzziches R,Francomano D,Gareri P,Lenzi A,Aversa A

    更新日期:2013-07-01 00:00:00

  • Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.

    abstract::The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2017.1395021

    authors: Reginster JY,Al Daghri NM,Bruyere O

    更新日期:2017-12-01 00:00:00

  • Bendamustine for treatment of chronic lymphocytic leukemia.

    abstract:INTRODUCTION:Chronic lymphocytic leukemia (CLL) often has an extended disease course. With a median age at diagnosis of 72 years, newer treatment options with less toxicity than standard nucleoside analogue-based regimens are needed. Historically, few therapy options are available once CLL has become refractory to nucl...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.693163

    authors: Chang JE,Kahl BS

    更新日期:2012-07-01 00:00:00

  • Current status in the pharmacological management of interstitial cystitis.

    abstract::Interstitial cystitis is a clinical condition occurring predominantly in women characterised by irritative voiding symptoms in the form of urinary frequency, urgency and pain. Patient symptoms have the potential to significantly affect quality of life, posing a challenge to some to perform activities of daily living. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.11.1967

    authors: Lukban JC

    更新日期:2003-11-01 00:00:00

  • Emerging antiretroviral drugs.

    abstract:INTRODUCTION:The potency, tolerability and convenience of antiretroviral agents have all significantly improved over the past years, making lifelong HIV therapy easier. However, several specific needs are still unmet, including low daily pill burden, friendly metabolic profile, lack of (or few) drug interactions and hi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.863277

    authors: Fernández-Montero JV,Vispo E,Soriano V

    更新日期:2014-02-01 00:00:00

  • Neratinib for the treatment of breast cancer.

    abstract:INTRODUCTION:Neratinib is an orally available, pan-HER inhibitor with clinical activity in patients with HER2-amplified and HER2-mutated breast cancer. Areas covered: A summary of publically available and relevant clinical data on neratinib. Expert opinion: Neratinib (N) is clearly distinct from lapatinib (L), a differ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2016.1244528

    authors: Prové A,Dirix L

    更新日期:2016-11-01 00:00:00

  • Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.

    abstract:INTRODUCTION:Breast cancer (BC) remains the most frequently diagnosed cancer and the most common cause of cancer death among women of all races worldwide. Over 80% of BC cases are hormone receptor (HR)-positive, comprised of luminal A and luminal B per molecular subtypes, imposing an urgent need to fully understand the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1429407

    authors: Duso BA,Trapani D,Viale G,Criscitiello C,D'Amico P,Belli C,Mazzarella L,Locatelli M,Minchella I,Curigliano G

    更新日期:2018-02-01 00:00:00

  • The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension.

    abstract:OBJECTIVE:The study investigated the efficacy and tolerability of teneligliptin co-administered to patients with type 2 diabetes mellitus (T2DM) who were inadequately controlled by stable metformin monotherapy ≥ 1000 mg/day. METHODS:A total of 447 patients from 55 European centers who completed a 14-day screening and ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14656566.2016.1190334

    authors: Bryson A,Jennings PE,Deak L,Paveliu FS,Lawson M

    更新日期:2016-07-01 00:00:00

  • A pharmacogeneticist's look at drug effects and the drug development process: an overview.

    abstract::This paper describes the functional roles of the closely related pharmacogenetic and pharmacogenomic sciences in medicine. Firstly, they provide means for a better understanding of the function of drugs, and particularly of the differences of drug action between individuals and also between racially categorised popula...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.8.1299

    authors: Kalow W

    更新日期:2005-07-01 00:00:00

  • Several options for antiviral treatment trials in multiple sclerosis--but which targets should be selected?

    abstract::Involvement of viruses in the pathogenesis of multiple sclerosis (MS) is a long-lived hypothesis, which is has not yet been proven nor refuted. This is partly due to difficulties in the evaluation of diagnostic findings on persistent infections by common viruses such as herpesviruses and endogenous retroviruses. Progr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.6.1087

    authors: Bergström T

    更新日期:2000-09-01 00:00:00

  • An evaluation of tofacitinib for the treatment of psoriatic arthritis.

    abstract::Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory condition that is associated with progressive joint destruction and reduced quality of life. Despite the common use of disease-modifying anti-rheumatic drugs (DMARDs) in PsA, their influence has been investigated in a number of studies with conflicting ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1657404

    authors: Abdulrahim H,Sharlala H,Adebajo AO

    更新日期:2019-11-01 00:00:00

  • Pharmacological management of depression in patients with multiple sclerosis.

    abstract:INTRODUCTION:The pharmacotherapeutic management of depression in patients with multiple sclerosis (MS) is a matter of debate that cannot be decided from the evidence available in the current literature. Therefore, its management essentially relies on the clinical experience of the prescribing clinician rather than on e...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1516207

    authors: Carta MG,Paribello P,Anastasia A,De Berardis D,Nardi AE,Fornaro M

    更新日期:2018-10-01 00:00:00

  • Erectile dysfunction, cardiovascular diseases and depression: interaction of therapy.

    abstract::Several studies have revealed the intimate associations between erectile dysfunction (ED), ischemic heart disease (IHD) and depression. Whether the physicians should also screen for the other two components when a patient presents with one component of this triad is still an important question to be answered. These th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903089326

    authors: El-Sakka AI,Shamloul R,Yassin AA

    更新日期:2009-09-01 00:00:00

  • Pharmacotherapy of large B-cell lymphoma.

    abstract:BACKGROUND:Constituting approximately 30% of lymphoid malignancies, diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma in adults worldwide. The clinical and biologic heterogeneity that exists in DLBCL suggests that this entity might actually be comprised of several distinct neoplasms that coul...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.13.2247

    authors: Escalón MP,Lossos IS

    更新日期:2008-09-01 00:00:00

  • Intramuscular Midazolam for treatment of Status Epilepticus.

    abstract:INTRODUCTION:Status epilepticus (SE) is a common neurological and medical emergency. It has high mortality and morbidity rates, which typically correlate with seizure semiology and duration; therefore, prompt and proper pharmacological intervention is paramount. In a pre-hospital setting, establishing venous access can...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1810236

    authors: Riva A,Iapadre G,Grasso EA,Balagura G,Striano P,Verrotti A

    更新日期:2021-01-01 00:00:00

  • Vaginal ring delivery of hormone replacement therapy--a review.

    abstract::Vaginal ring delivery systems are a highly promising approach to hormone replacement therapy (HRT). The vagina is an excellent route for steroid absorption. Menopausal vaginal rings can be designed to allow very low dose local delivery of oestrogen to the vagina for the large percentage of postmenopausal women experie...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.2.201

    authors: Dezarnaulds G,Fraser IS

    更新日期:2003-02-01 00:00:00

  • Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.

    abstract:INTRODUCTION:Patisiran and inotersen are two therapies approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, a rapidly progressive disease with a substantial clinical burden. This analysis indirectly compares the efficacy of patisiran and inotersen on neuropathy and qu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1811850

    authors: Gorevic P,Franklin J,Chen J,Sajeev G,Wang JCH,Lin H

    更新日期:2021-01-01 00:00:00

  • The pharmacologic management of multiple myeloma in older adults.

    abstract:INTRODUCTION:Multiple myeloma is a disease predominately affecting older adults. Pivotal to treating older adults is understanding their physiologic differences compared to younger subjects and how the complexity of therapies has an impact upon this patient population. AREAS COVERED:Herein, the authors address the eff...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1577822

    authors: Dempsey JL,Johns A,Rosko AE,Lazarus HM

    更新日期:2019-05-01 00:00:00

  • Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?

    abstract:INTRODUCTION:When estimating the cost-effectiveness or budget impact of chronic obstructive pulmonary disease (COPD) medication, it is common practice to use trial data for clinical inputs. However, such inputs do not always reflect the real-world situation. Previous reviews recognized the need for taking real-world da...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2021.1873953

    authors: Fens T,Zhou G,Postma MJ,van Puijenbroek EP,van Boven JFM

    更新日期:2021-01-13 00:00:00

  • Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives.

    abstract:INTRODUCTION:Hodgkin lymphoma (HL) is a lymphoid malignancy with an incidence of 2 - 3/100,000/year. Young adults are most often affected. Due to the development of highly active multi-agent chemotherapy protocols and the optimization of radiotherapy (RT) fields and doses, HL has become one of the malignancies with the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.909411

    authors: Eichenauer DA,Böll B,Diehl V

    更新日期:2014-06-01 00:00:00

  • Pharmacotherapy of cough-variant asthma.

    abstract::Cough-variant asthma is considered as an asthma subset in which chronic cough is the only symptom. It is believed to be more frequent and, hence, sometimes overdiagnosed in children, and shares with typical asthma eosinophilic airway inflammation and consequent bronchial hyper-responsiveness. Presently available thera...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.17.3021

    authors: Antoniu SA,Mihaescu T,Donner CF

    更新日期:2007-12-01 00:00:00

  • Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.

    abstract:OBJECTIVE:To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chronic patients (>3 years). RESEARCH DESIGN AND METHODS:Post hoc analysis o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究

    doi:10.1080/14656566.2016.1174692

    authors: Hargarter L,Bergmans P,Cherubin P,Keim S,Conca A,Serrano-Blanco A,Bitter I,Bilanakis N,Schreiner A

    更新日期:2016-06-01 00:00:00

  • Drug-eluting stents for acute myocardial infarction.

    abstract::This is a review of the literature comparing the efficacy and safety of drug-eluting stents (DES) versus bare-metal stents (BMS) in patients with acute myocardial infarction (MI). The present article reviews whether DES are beneficial in the setting of primary percutaneous coronary intervention (PCI), and this has bee...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560802627952

    authors: Yeter E,Kurt M,Silay Y,Anderson HV,Denktas AE

    更新日期:2009-01-01 00:00:00

  • Pharmacological treatment options for panic disorder in children and adolescents.

    abstract::Although panic disorder usually emerges in early to middle adulthood, adults with panic disorder often retrospectively report that their panic symptoms began in childhood or early adolescence. The majority of these juvenile cases are being misdiagnosed, and/or do not come to clinical attention. Awareness of early-onse...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.5.545

    authors: Masi G,Pari C,Millepiedi S

    更新日期:2006-04-01 00:00:00